Agilent Technologies Inc. Introduces First DNA Methylation Target-Enrichment System for Disease Research

MARCO ISLAND, Fla.--(BUSINESS WIRE)--(AGBT) – Agilent Technologies Inc. (NYSE:A) today expanded its target-enrichment platform with the SureSelect XT Human Methyl-Seq system for epigenetic research into DNA methylation sites. It is the first comprehensive DNA methylation discovery system using target enrichment. Agilent will unveil the product at the Advances in Genome Biology and Technology meeting here tomorrow.